TGFB1 and central nervous system cancer: Multiple immunomodulatory cytokines have or are being investigated for clinical use, including TGF-β, CSF-1, IL-2, IL-7, IL-10, IL-12, IL-18, IL-21, IL-22, and IFN-α, some of which include glioma patients (Table 2).